drugset
drugset / Trial / NCT07389239

A Study Evaluating the Immunotherapy Treatment for Ovarian Cancer and Other Advanced Malignancies.

NCT07389239 ↗

Phase 1/2 Not yet recruiting 24 enrolled University of Chicago
Non-randomizedSequentialOpen-labelTreatment

Summary

This phase I/IIA trial studies the side effects and best dose of gene-modified T cells when given with or without decitabine, and to see how well they work in treating patients with malignancies expressing cancer-testis antigens.

Timeline

Start
2026-06-23
Primary completion
2031-12-10
Completion
2031-12-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Decitabine Small molecule 15 mg/m2 Oral
Subject NY-ESO-1 TCR/ dnTGFβRII Cell therapy — —
Background Cyclophosphamide Other / unclassified 45 mg/kg Intravenous
Background aldesleukin Protein / enzyme biologic 500000 unknown Oral

Indications

ovarian cancer